出血性疾患検査の世界市場予測（～2028年）：製品別、薬剤クラス別、治療別、適応症別、エンドユーザー別、地域別の分析

世界の出血性疾患検査の市場規模は、2022年に8,850万米ドルとなり、予測期間中に9.7％のCAGRで成長を遂げ、2028年までに1億5,508万米ドルに達すると予測されています。

当レポートでは、世界の出血性疾患検査市場を調査し、市場の促進要因・抑制要因、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界の出血性疾患検査市場：製品別

• 試薬
• 消耗品
• 機器
• その他の製品

第6章 世界の出血性疾患検査市場：薬剤クラス別

• フィブリンシーラント
• 酢酸デスモプレシン
• 抗線溶薬
• 血漿由来凝固因子濃縮物
• 組換え凝固因子濃縮物
• その他の薬剤クラス

第7章 世界の出血性疾患検査市場：治療別

• ホルモン補充療法
• 避妊薬
• 凝固安定剤
• デスモプレシン
• フィブリンシーラント
• パイプライン分析
• 切り傷用薬品
• その他の治療

第8章 世界の出血性疾患検査市場：適応症別

• フォン・ヴィレブランド病
• 血友病A
• 血友病B
• その他の適応症

第9章 世界の出血性疾患検査市場：エンドユーザー別

• 研究
• 病院
• 診療所
• その他のエンドユーザー

第10章 世界の出血性疾患検査市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第11章 主な動向

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 拡張
• その他の主な戦略

第12章 企業プロファイル

• Sysmex Corporation
• Siemens Healthcare GmbH
• Alexion Pharmaceuticals
• Abbott
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Biogen Inc
• Alnylam Pharmaceuticals Inc.
• Pfizer Inc
• HORIBA Ltd
• Bayer AG
• Xenetic Biosciences Inc
• Thermo Fisher Scientific Inc
• CSL Behring
• Sanofi S.A
• Catalyst Biosciences
• Grifols, S.A
• Octapharma Plasma, Inc
• Bristol-Myers Squibb
• Johnson & Johnson
• Sun Pharma Industries Limited
• Kedrion Biopharma Inc
• Teva Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company
• Dimension Therapeutics Inc
• Novo Nordisk A/S
• Ferring Pharmaceuticals

List of Tables

• Table 1 Global Bleeding Disorder Testing Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 3 Global Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 4 Global Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 5 Global Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 6 Global Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 7 Global Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 8 Global Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 9 Global Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 10 Global Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 11 Global Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 12 Global Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 13 Global Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 14 Global Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 15 Global Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 16 Global Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 17 Global Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 18 Global Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 19 Global Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 20 Global Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 21 Global Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 22 Global Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 23 Global Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 24 Global Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 25 Global Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 26 Global Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 27 Global Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 28 Global Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 29 Global Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 30 Global Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 31 Global Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 32 Global Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 33 North America Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
• Table 34 North America Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 35 North America Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 36 North America Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 37 North America Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 38 North America Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 39 North America Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 40 North America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 41 North America Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 42 North America Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 43 North America Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 44 North America Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 45 North America Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 46 North America Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 47 North America Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 48 North America Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 49 North America Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 50 North America Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 51 North America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 52 North America Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 53 North America Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 54 North America Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 55 North America Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 56 North America Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 57 North America Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 58 North America Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 59 North America Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 60 North America Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 61 North America Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 62 North America Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 63 North America Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 64 North America Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 65 Europe Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
• Table 66 Europe Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 67 Europe Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 68 Europe Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 69 Europe Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 70 Europe Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 71 Europe Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 72 Europe Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 73 Europe Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 74 Europe Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 75 Europe Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 76 Europe Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 77 Europe Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 78 Europe Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 79 Europe Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 80 Europe Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 81 Europe Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 82 Europe Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 83 Europe Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 84 Europe Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 85 Europe Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 86 Europe Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 87 Europe Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 88 Europe Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 89 Europe Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 90 Europe Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 91 Europe Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 92 Europe Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 93 Europe Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 94 Europe Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 95 Europe Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 96 Europe Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 97 Asia Pacific Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
• Table 98 Asia Pacific Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 99 Asia Pacific Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 100 Asia Pacific Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 101 Asia Pacific Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 102 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 103 Asia Pacific Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 104 Asia Pacific Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 105 Asia Pacific Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 106 Asia Pacific Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 107 Asia Pacific Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 108 Asia Pacific Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 109 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 110 Asia Pacific Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 111 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 112 Asia Pacific Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 113 Asia Pacific Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 114 Asia Pacific Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 115 Asia Pacific Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 116 Asia Pacific Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 117 Asia Pacific Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 118 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 119 Asia Pacific Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 120 Asia Pacific Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 121 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 122 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 123 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 124 Asia Pacific Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 125 Asia Pacific Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 126 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 127 Asia Pacific Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 128 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 129 South America Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
• Table 130 South America Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 131 South America Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 132 South America Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 133 South America Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 134 South America Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 135 South America Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 136 South America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 137 South America Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 138 South America Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 139 South America Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 140 South America Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 141 South America Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 142 South America Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 143 South America Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 144 South America Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 145 South America Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 146 South America Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 147 South America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 148 South America Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 149 South America Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 150 South America Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 151 South America Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 152 South America Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 153 South America Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 154 South America Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 155 South America Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 156 South America Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 157 South America Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 158 South America Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 159 South America Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 160 South America Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 161 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
• Table 162 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
• Table 163 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
• Table 164 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
• Table 165 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
• Table 166 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
• Table 167 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 168 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 169 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
• Table 170 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
• Table 171 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 172 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
• Table 173 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 174 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
• Table 175 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
• Table 176 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
• Table 177 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
• Table 178 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
• Table 179 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
• Table 180 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
• Table 181 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
• Table 182 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
• Table 183 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
• Table 184 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
• Table 185 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
• Table 186 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
• Table 187 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
• Table 188 Middle East & Africa Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
• Table 189 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
• Table 190 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
• Table 191 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
• Table 192 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)

According to Stratistics MRC, the Global Bleeding Disorder Testing Market is accounted for $88.5 million in 2022 and is expected to reach $155.08 million by 2028 growing at a CAGR of 9.7% during the forecast period. Bleeding disorders occur when the body's ability to clot blood is impaired. A clot forms on the infected body part, which is made up of platelets and a specific type of blood cell. This clot prevents germs from entering the blood and also prevents blood from draining from the injured area. Bleeding disorder testing can help determine whether certain clotting factors are involved and measures how long it takes blood to clot. The test evaluates how long it takes the vessels cut to constrict and how long it takes for platelets in the blood to seal off the hole.

According to the National Hemophilia Foundation, Von Willebrand disease is the most common bleeding disorder affecting approximately 1 in every 100 people or up to 1% of the U.S population.

Market Dynamics:

Driver:

The rise in the blood related disorders

Blood related disorders are chronic illness. They are also life threatening as they circulate throughout the blood. Disorders such as liver disorders, anaemia, and other blood coagulation disorders increased and raised the demand for bleeding disorders treatment. These inherited disorders brought lucrative growth in the market.

Restraint:

Scarcity of skilled professionals

The scarcity of skilled professionals and trained expertise will be a major impediment to the growth of the bleeding disorders treatment market. Medication costs will also slow the market's growth rate. Inadequate reimbursement policies will also limit the scope. Unprofessional treatments can cause major impact on the patient's health. This challenge is hindering the growth of the market.

Opportunity:

Government investments for healthcare interoperability

The increase in the funding by the federal government to drive the adoption of these solutions further influences the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market and fueling the market growth.

Threat:

Low adherence to guidelines

The lower focus of the national organizations and other institutions in emerging countries towards increasing the awareness regarding these conditions resulting in the low penetration of testing. This challenge is limiting the early diagnosis and proper care of patients which is hindering the market growth.

COVID-19 Impact

The COVID-19 pandemic has had a major long-term positive impact on the bleeding disorders treatment market. Initially, there was a drop in the market as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased exponentially and made the market to sustain.

The product segment is expected to be the largest during the forecast period

The product segment is estimated to have a lucrative growth, due to developing healthcare infrastructure and healthcare access. The rising awareness regarding the disorders are leading to increased demand. Advancements in technology are improving automation and portable analyzers are anticipated to the growth of the market.

The hospital segment is expected to have the highest CAGR during the forecast period

The hospital segment is anticipated to witness the fastest CAGR growth during the forecast period, due to rising technology treatment of the disorders. The hospitals rate is increasing due to the severity of these disorders which is leading to an increased demand of testing instruments and reagents in hospitals and clinics which is propelling the market growth.

Region with highest share:

Europe is projected to hold the largest market share during the forecast period owing to the growing prevalence of disorders in the region. The rising faithfulness to guidelines and the growing patient population increased the demand. The testing instruments and devices are very advanced in this region which propelled the market share.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the growing launch of testing instruments and the escalating number of regulatory approvals. The increasing awareness and diagnosis rate of bleeding disorder has anticipated to fuel the market growth.

Key players in the market

Some of the key players profiled in the Bleeding Disorder Testing Market include Sysmex Corporation, Siemens Healthcare GmbH, Alexion Pharmaceuticals, Abbott, Amgen Inc, F. Hoffmann-La Roche Ltd, Biogen Inc, Alnylam Pharmaceuticals Inc, Pfizer Inc, HORIBA Ltd, Bayer AG, Xenetic Biosciences Inc, Thermo Fisher Scientific Inc, CSL Behring, Sanofi S.A, Catalyst Biosciences, Grifols, S.A, Octapharma Plasma, Inc, Bristol-Myers Squibb, Johnson & Johnson, Sun Pharma Industries Limited, Kedrion Biopharma Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, Dimension Therapeutics Inc, Novo Nordisk A/S, Ferring Pharmaceuticals

Key Developments:

In March 2021, F. Hoffmann La Roche Ltd, launched 8 new configurations for Cobas pro integrated solutions with an aim to maximize throughput and increase testing efficiency.

In Feb 2020, Novo Nordisk A/S launched Esperoct, an anti-hemophilic factor, in the United States in February 2020 for the treatment of adults and children with haemophilia A, i.e., to reduce and control bleeding episodes even during surgery.

Products Covered:

• Reagents
• Consumables
• Instruments
• Other Products

Drug Classes Covered:

• Fibrin Sealants
• Desmopressin Acetate
• Antifibrinolytics
• Plasma Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Other Drug Classes

Treatments Covered:

• Hormone Replacement Therapy
• Contraceptives
• Clot Stabilizing Drugs
• Desmopressin
• Fibrin Sealants
• Pipeline Analysis
• Drugs Applied To Cuts
• Other Treatments

Indications Covered:

• Von Willebrand Disease
• Hemophilia A
• Hemophilia B
• Other Indications

End Users Covered:

• Research Institutes
• Hospital
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Bleeding Disorder Testing Market, By Product

• 5.1 Introduction
• 5.2 Reagents
• 5.3 Consumables
• 5.4 Instruments
• 5.5 Other Products

6 Global Bleeding Disorder Testing Market, By Drug Class

• 6.1 Introduction
• 6.2 Fibrin Sealants
• 6.3 Desmopressin Acetate
• 6.4 Antifibrinolytics
• 6.5 Plasma Derived Coagulation Factor Concentrates
• 6.6 Recombinant Coagulation Factor Concentrates
• 6.7 Other Drug Classes

7 Global Bleeding Disorder Testing Market, By Treatment

• 7.1 Introduction
• 7.2 Hormone Replacement Therapy
• 7.3 Contraceptives
• 7.4 Clot Stabilizing Drugs
• 7.5 Desmopressin
• 7.6 Fibrin Sealants
• 7.7 Pipeline Analysis
• 7.8 Drugs Applied To Cuts
• 7.9 Other Treatments

8 Global Bleeding Disorder Testing Market, By Indication

• 8.1 Introduction
• 8.2 Von Willebrand Disease
• 8.3 Hemophilia A
• 8.4 Hemophilia B
• 8.5 Other Indications

9 Global Bleeding Disorder Testing Market, By End User

• 9.1 Introduction
• 9.2 Research Institutes
• 9.3 Hospital
• 9.4 Clinics
• 9.5 Other End Users

10 Global Bleeding Disorder Testing Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Sysmex Corporation
• 12.2 Siemens Healthcare GmbH
• 12.3 Alexion Pharmaceuticals
• 12.4 Abbott
• 12.5 Amgen Inc
• 12.6 F. Hoffmann-La Roche Ltd
• 12.7 Biogen Inc
• 12.8 Alnylam Pharmaceuticals Inc.
• 12.9 Pfizer Inc
• 12.10 HORIBA Ltd
• 12.11 Bayer AG
• 12.13 Xenetic Biosciences Inc
• 12.12 Thermo Fisher Scientific Inc
• 12.14 CSL Behring
• 12.15 Sanofi S.A
• 12.16 Catalyst Biosciences
• 12.17 Grifols, S.A
• 12.18 Octapharma Plasma, Inc
• 12.19 Bristol-Myers Squibb
• 12.2 Johnson & Johnson
• 12.21 Sun Pharma Industries Limited
• 12.22 Kedrion Biopharma Inc
• 12.23 Teva Pharmaceutical Industries Ltd
• 12.24 Takeda Pharmaceutical Company
• 12.25 Dimension Therapeutics Inc
• 12.26 Novo Nordisk A/S
• 12.27 Ferring Pharmaceuticals